Mysoline
(Primidone)PreclinicalSmall molecule
Mysoline is one of 11 small molecule programs targeting Essential Tremor. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
10
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Essential Tremor
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Epidiolex
Jazz PharmaceuticalsApproved
Marinol
Jazz PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Topamax
WWim Janssens
Approved
AGN-151607-DP
AbbViePhase 2
BP1.4979
BBioprojet
Phase 2
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Alcohol
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clopidogrel1 trial
Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant
Withdrawn·—·Phase 2·NCT02008123
Fasting Conditions1 trial
Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions
Completed·—·Phase 1·NCT01132040·24 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
MYSOLINE
NDA NDA009170
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Primidone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- VValeant Pharmaceuticals